Cargando…

Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically

The proteins soluble ST2 (sST2) and galectin-3 are currently gaining mounting interest as candidate biomarkers in cardiac disease. Both, sST2 and galectin-3 have been included in the 2013 ACCF/AHA guideline for additive risk stratification of patients with acute and chronic heart failure. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Thomas, Dieplinger, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Communications and Publications Division (CPD) of the IFCC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009947/
https://www.ncbi.nlm.nih.gov/pubmed/27683536
_version_ 1782451603618398208
author Mueller, Thomas
Dieplinger, Benjamin
author_facet Mueller, Thomas
Dieplinger, Benjamin
author_sort Mueller, Thomas
collection PubMed
description The proteins soluble ST2 (sST2) and galectin-3 are currently gaining mounting interest as candidate biomarkers in cardiac disease. Both, sST2 and galectin-3 have been included in the 2013 ACCF/AHA guideline for additive risk stratification of patients with acute and chronic heart failure. The aim of this review is to provide information on analytical considerations of measuring circulating sST2 and galectin-3 including knowledge on in vitro stability, biological variation and reference ranges of both analytes.
format Online
Article
Text
id pubmed-5009947
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Communications and Publications Division (CPD) of the IFCC
record_format MEDLINE/PubMed
spelling pubmed-50099472016-09-28 Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically Mueller, Thomas Dieplinger, Benjamin EJIFCC Research Article The proteins soluble ST2 (sST2) and galectin-3 are currently gaining mounting interest as candidate biomarkers in cardiac disease. Both, sST2 and galectin-3 have been included in the 2013 ACCF/AHA guideline for additive risk stratification of patients with acute and chronic heart failure. The aim of this review is to provide information on analytical considerations of measuring circulating sST2 and galectin-3 including knowledge on in vitro stability, biological variation and reference ranges of both analytes. The Communications and Publications Division (CPD) of the IFCC 2016-07-01 /pmc/articles/PMC5009947/ /pubmed/27683536 Text en Copyright © 2016 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mueller, Thomas
Dieplinger, Benjamin
Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
title Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
title_full Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
title_fullStr Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
title_full_unstemmed Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
title_short Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
title_sort soluble st2 and galectin-3: what we know and don’t know analytically
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009947/
https://www.ncbi.nlm.nih.gov/pubmed/27683536
work_keys_str_mv AT muellerthomas solublest2andgalectin3whatweknowanddontknowanalytically
AT dieplingerbenjamin solublest2andgalectin3whatweknowanddontknowanalytically